Aquilo Capital Management

Precision BioSciences, founded in 2006, is a biotechnology company headquartered in Durham, North Carolina. It specializes in genome editing, developing therapeutic products using its proprietary ARCUS technology. The company focuses on creating allogeneic CAR T immunotherapies to treat cancers like acute lymphoblastic leukemia and non-hodgkin lymphoma, as well as genetic disorders.

Sensorion is a France-based biopharmaceutical company focused on developing therapies for inner ear disorders. The company pursues programs to treat hearing and balance impairments, including SENS-401 for sudden sensorineural hearing loss and SENS-111 for acute unilateral vestibulopathy, with SENS-300 in preclinical development for inner ear protection. Sensorion conducts research and development to restore hearing and vestibular function and pursues collaboration opportunities, including a strategic partnership with Cochlear Limited to study combination therapies for cochlear implant patients.

Amryt Pharma is a specialty biopharmaceutical company headquartered in London that develops and commercialises therapies for rare and orphan diseases. Its commercial portfolio includes Myalept, a leptin replacement used with diet to treat lipodystrophy, and Lojuxta, a lipid‑lowering agent for homozygous familial hypercholesterolaemia. The company also markets Episalvan, a wound‑healing product approved in the EU for partial‑thickness wounds, and is advancing it for epidermolysis bullosa. In early‑stage development, Amryt is pursuing FILSUVEZ for cutaneous manifestations of epidermolysis bullosa and AP103, a gene‑therapy platform for recessive dystrophic epidermolysis bullosa, as well as next‑generation somatostatin analogues for neuroendocrine disorders such as acromegaly and Cushing’s disease. Products are sold in the Americas, Europe and the Middle East.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on the development of anticalin-based therapeutics for treating various medical conditions, including cancer and severe asthma. Anticalins are engineered proteins derived from lipocalins, naturally occurring human proteins that can bind and transport a variety of molecules. The company's lead programs include PRS-060, a drug candidate in Phase I clinical trials targeting IL-4Ra for asthma and inflammatory diseases, and PRS-343, a bispecific protein in Phase I trials for oncology. Pieris is also advancing PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development, and PRS-080, currently in Phase IIa trials for targeting hepcidin in patients with functional iron deficiency. Pieris collaborates with strategic partners and research institutions to enhance its development efforts, showcasing a robust pipeline aimed at addressing significant unmet medical needs. The company was founded in 2000 and is recognized for its innovative approach in biotherapeutics.